News: Novartis AG (NVS.N)

NVS.N on New York Stock Exchange

95.30USD
22 Dec 2014
Price Change (% chg)

$0.69 (+0.73%)
Prev Close
$94.61
Open
$95.21
Day's High
$95.54
Day's Low
$95.03
Volume
325,002
Avg. Vol
303,833
52-wk High
$96.97
52-wk Low
$77.92

Search Stocks
Select another date:

Lilly must divest Sentinel products after FTC nod on Novartis deal

WASHINGTON - Eli Lilly and Co has won approval to buy Novartis AG's animal health unit on condition that it divests its Sentinel line of products for treating heartworm in dogs, the Federal Trade Commission said on Monday.

Lilly must divest Sentinel products after FTC nod on Novartis deal

WASHINGTON - Eli Lilly and Co has won approval to buy Novartis AG's animal health unit on condition that it divests its Sentinel line of products for treating heartworm in dogs, the Federal Trade Commission said on Monday.

Lilly to divest some Sentinel products to win approval on Novartis

WASHINGTON, Dec 22 - Eli Lilly and Co has won approval to buy Novartis AG's animal health unit on condition that it divest the Sentinel line of products for treating heartworm in dogs, the Federal Trade Commission said on Monday.

Morphosys gets payment from Novartis for oncology research

FRANKFURT, Dec 22 - Morphosys AG on Monday said it had received a payment from Novartis in connection with the initiation of a phase 1 clinical trial of a HuCAL antibody in the field of oncology.

GSK shareholders approve asset swap deal with Novartis

LONDON, Dec 18 - Shareholders in British drugmaker GlaxoSmithKline have approved a planned deal with Switzerland's Novartis, which will see the two pharmaceutical groups trade more than $20 billion of assets.

Fitch Affirms GlaxoSmithKline PLC at 'A+'; Revises Outlook to Negative

(The following statement was released by the rating agency) LONDON, December 17 (Fitch) Fitch Ratings has affirmed UK-based pharmaceuticals company GlaxoSmithKline PLC's (GSK) Long-term Issuer Default Rating (IDR) and senior unsecured rating at 'A+'. The Outlook has been revised to Negative from Stable. Fitch has also affirmed the senior unsecured rating of 'A+' for the debt issued under GlaxoSmithKline Capital PLC. The Negative Outlook encapsulates Fitch's expectation of increasing financia

Novartis sues India's Cipla over respiratory drug Onbrez

MUMBAI - Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price.

Novartis sues India's Cipla over respiratory drug Onbrez

MUMBAI, Dec 17 - Swiss drugmaker Novartis AG said on Wednesday it had sued India's Cipla Ltd for infringing patents covering its respiratory drug Onbrez, a month after Cipla launched a copy at a fifth of the original drug's price.

Novartis buys 12.8 percent stake in BioLineRX in co-development deal

JERUSALEM - Swiss drugmaker Novartis AG bought a 12.8 percent stake in Israeli biopharmaceutical company BioLineRX Ltd as part of a multi-year collaboration deal, BioLineRX said on Tuesday.

Novartis buys 12.8 pct stake in BioLineRX in co-development deal

JERUSALEM, Dec 16 - Swiss drugmaker Novartis AG bought a 12.8 percent stake in Israeli biopharmaceutical company BioLineRX Ltd as part of a multi-year collaboration deal, BioLineRX said on Tuesday.

Select another date:
Search Stocks